At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CNSP CNS Pharmaceuticals, Inc.
Market Closed 07-02 16:00:00 EDT
5.07
+0.39
+8.33%
盘后4.81
-0.26-5.13%
19:14 EDT
High5.07
Low4.66
Vol11.08K
Open5.02
D1 Closing4.68
Amplitude8.87%
Mkt Cap7.41M
Tradable Cap6.87M
Total Shares1.46M
T/O54.34K
T/O Rate0.82%
Tradable Shares1.35M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
CNS Pharma director Faith L. Charles buys 7,100 shares for $34,000
CNS Pharmaceuticals to Pursue Acquisition and In-Licensing of Neurology and Oncology Assets, While Exploring Out-Licensing of Berubicin and TPI 287 to Build a New Pipeline
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.